↓ Skip to main content

Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

twitter
17 tweeters

Readers on

mendeley
53 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice
Published in
Journal for Immunotherapy of Cancer, June 2017
DOI 10.1186/s40425-017-0256-z
Pubmed ID
Authors

Weiqing Jing, Jill A. Gershan, Grace C. Blitzer, Katie Palen, James Weber, Laura McOlash, Matthew Riese, Bryon D. Johnson

Abstract

Adoptive cellular therapy (ACT) with cancer antigen-reactive T cells following lymphodepletive pre-conditioning has emerged as a potentially curative therapy for patients with advanced cancers. However, identification and enrichment of appropriate T cell subsets for cancer eradication remains a major challenge for hematologic cancers. PD-1(+) and PD-1(-) T cell subsets from myeloma-bearing mice were sorted and analyzed for myeloma reactivity in vitro. In addition, the T cells were activated and expanded in culture and given to syngeneic myeloma-bearing mice as ACT. Myeloma-reactive T cells were enriched in the PD-1(+) cell subset. Similar results were also observed in a mouse AML model. PD-1(+) T cells from myeloma-bearing mice were found to be functional, they could be activated and expanded ex vivo, and they maintained their anti-myeloma reactivity after expansion. Adoptive transfer of ex vivo-expanded PD-1(+) T cells together with a PD-L1 blocking antibody eliminated established myeloma in Rag-deficient mice. Both CD8 and CD4 T cell subsets were important for eradicating myeloma. Adoptively transferred PD-1(+) T cells persisted in recipient mice and were able to mount an adaptive memory immune response. These results demonstrate that PD-1 is a biomarker for functional myeloma-specific T cells, and that activated and expanded PD-1(+) T cells can be effective as ACT for myeloma. Furthermore, this strategy could be useful for treating other hematologic cancers.

Twitter Demographics

The data shown below were collected from the profiles of 17 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 52 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 17%
Researcher 8 15%
Student > Master 7 13%
Student > Doctoral Student 5 9%
Other 4 8%
Other 7 13%
Unknown 13 25%
Readers by discipline Count As %
Medicine and Dentistry 11 21%
Immunology and Microbiology 8 15%
Biochemistry, Genetics and Molecular Biology 7 13%
Agricultural and Biological Sciences 5 9%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Other 7 13%
Unknown 13 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 July 2017.
All research outputs
#2,082,131
of 15,921,004 outputs
Outputs from Journal for Immunotherapy of Cancer
#316
of 1,310 outputs
Outputs of similar age
#50,863
of 270,098 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 15,921,004 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,310 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.5. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,098 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them